A Phase 2 interventional study of MK-0893 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 85th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 10 in phase 2, and was the 39th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 92nd largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 21 in phase 2, and was the 49th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MK-0893 · Drug: Sitagliptin · Drug: Placebo for Metformin
Drug: MK-0893 · Drug: Metformin · Drug: Placebo for Sitagliptin
Drug: Sitagliptin · Drug: Metformin · Drug: Placebo for MK-0893
Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
Also known as: JANUVIA™, MK0431
Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
Also known as: GLUCOPHAGE®
Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels
Time frame: BL, 4 weeks (end of double-blind treatment period)
Change From BL to Week 4 in Fasting Plasma Glucose (FPG)
Time frame: BL, 4 weeks (end of double-blind treatment period)
Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)
Time frame: BL, 4 weeks (end of double-blind treatment period)
Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC
Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.
Time frame: BL, 4 weeks (end of double-blind treatment period)
Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC
GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.
Time frame: BL, 4 weeks (end of double-blind treatment period)
| Milestone | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Started | 48 | 49 | 49 |
| Completed post-treatment period | 44 | 47 | 47 |
| Completed | 44 | 47 | 47 |
| Not completed | 4 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| mg/dL | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels | -85.7 ± 4.6 | -117.4 ± 4.6 | -99.6 ± 4.6 |
| mg/dL | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Change From BL to Week 4 in Fasting Plasma Glucose (FPG) | -73.7 ± 4.4 | -101.9 ± 4.3 | -82.8 ± 4.3 |
| mg.h/dL | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC) | -187.7 ± 11.4 | -254.9 ± 11.1 | -210.3 ± 11.4 |
Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.
| pmol*h/L | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC | 7.4 ± 1.0 | 16.4 ± 1.0 | 3.2 ± 1.0 |
GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.
| pmole*h/L | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC | 11.0 ± 1.1 | 6.3 ± 1.1 | 17.6 ± 1.1 |
Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-0893 + Sitagliptin | — | 0/48 (0%) | 7/48 (14.6%) |
| MK-0893 + Metformin | — | 0/49 (0%) | 10/49 (20.4%) |
| Sitagliptin + Metformin | — | 0/49 (0%) | 8/49 (16.3%) |
| Event | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin |
|---|---|---|---|
| diarrhoeaGastrointestinal disorders | 1/48 | 6/49 | 6/49 |
| upper respiratory tract infectionInfections and infestations | 4/48 | 1/49 | 1/49 |
| nauseaGastrointestinal disorders | 2/48 | 4/49 | 2/49 |
| Age, Continuous(years) | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin | Total |
|---|---|---|---|---|
| Mean | 53.6 ± 8.0 | 52.0 ± 9.7 | 53.8 ± 8.7 | 53.2 ± 8.8 |
| Gender(Participants) | MK-0893 + Sitagliptin | MK-0893 + Metformin | Sitagliptin + Metformin | Total |
|---|---|---|---|---|
| Female | 16 | 26 | 15 | 57 |
| Male | 32 | 23 | 34 | 89 |
No study locations are listed for this record.
The record gives a start of Feb 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mk-0893 · Sitagliptin · Metformin